Downregulation of cystine transporter xc- by irinotecan in human head and neck cancer FaDu xenografts

Sreenivasulu Chintala, Károly Tóth, Ming Biao Yin, Arup Bhattacharya, Sylvia B Smith, M. Shamsul Ola, Shousong Cao, Farukh A. Durrani, Tanjima R. Zinia, Rebecca Dean, Harry K. Slocum, Youcef M. Rustum

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The purpose of this study was: (1) to document the critical requirement of cystine for growth of human tumor cells in vitro, and (2) to determine the effect of the anticancer agent irinotecan on the cystine transporter xc- in head and neck FaDu xenografts. Methods: Cell growth was measured by sulforhodamine B assay. xCT protein, glutathione (GSH) and DNA damage were determined using Western blot, spectrophotometry, and immunohistochemistry, respectively. Results: Depletion of cystine from the medium inhibited tumor cell growth. Treatment of FaDu tumor with a therapeutic dose of irinotecan resulted in depression of xCT protein levels, leading to tumor growth retardation and downregulation of GSH with increased reactive oxygen species (ROS). The accumulation of ROS correlated with increased DNA damage as evidenced by increased H2AX. Conclusion: Depression of xCT protein by irinotecan resulted in downregulation of GSH and increase in ROS, which could be the other possible mechanisms of DNA damage by irinotecan.

Original languageEnglish (US)
Pages (from-to)223-233
Number of pages11
JournalChemotherapy
Volume56
Issue number3
DOIs
StatePublished - Jun 1 2010

Fingerprint

irinotecan
Cystine
Head and Neck Neoplasms
Heterografts
Down-Regulation
DNA Damage
Reactive Oxygen Species
Growth
lissamine rhodamine B
Neoplasms
Proteins
Spectrophotometry
Antineoplastic Agents
Glutathione
Neck
Western Blotting
Immunohistochemistry
Head
Therapeutics

Keywords

  • Glutathione
  • Irinotecan
  • P-H2AX
  • SN-38
  • XCT

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Chintala, S., Tóth, K., Yin, M. B., Bhattacharya, A., Smith, S. B., Ola, M. S., ... Rustum, Y. M. (2010). Downregulation of cystine transporter xc- by irinotecan in human head and neck cancer FaDu xenografts. Chemotherapy, 56(3), 223-233. https://doi.org/10.1159/000316334

Downregulation of cystine transporter xc- by irinotecan in human head and neck cancer FaDu xenografts. / Chintala, Sreenivasulu; Tóth, Károly; Yin, Ming Biao; Bhattacharya, Arup; Smith, Sylvia B; Ola, M. Shamsul; Cao, Shousong; Durrani, Farukh A.; Zinia, Tanjima R.; Dean, Rebecca; Slocum, Harry K.; Rustum, Youcef M.

In: Chemotherapy, Vol. 56, No. 3, 01.06.2010, p. 223-233.

Research output: Contribution to journalArticle

Chintala, S, Tóth, K, Yin, MB, Bhattacharya, A, Smith, SB, Ola, MS, Cao, S, Durrani, FA, Zinia, TR, Dean, R, Slocum, HK & Rustum, YM 2010, 'Downregulation of cystine transporter xc- by irinotecan in human head and neck cancer FaDu xenografts', Chemotherapy, vol. 56, no. 3, pp. 223-233. https://doi.org/10.1159/000316334
Chintala, Sreenivasulu ; Tóth, Károly ; Yin, Ming Biao ; Bhattacharya, Arup ; Smith, Sylvia B ; Ola, M. Shamsul ; Cao, Shousong ; Durrani, Farukh A. ; Zinia, Tanjima R. ; Dean, Rebecca ; Slocum, Harry K. ; Rustum, Youcef M. / Downregulation of cystine transporter xc- by irinotecan in human head and neck cancer FaDu xenografts. In: Chemotherapy. 2010 ; Vol. 56, No. 3. pp. 223-233.
@article{634fdce369434f638e77490c1373771c,
title = "Downregulation of cystine transporter xc- by irinotecan in human head and neck cancer FaDu xenografts",
abstract = "Background: The purpose of this study was: (1) to document the critical requirement of cystine for growth of human tumor cells in vitro, and (2) to determine the effect of the anticancer agent irinotecan on the cystine transporter xc- in head and neck FaDu xenografts. Methods: Cell growth was measured by sulforhodamine B assay. xCT protein, glutathione (GSH) and DNA damage were determined using Western blot, spectrophotometry, and immunohistochemistry, respectively. Results: Depletion of cystine from the medium inhibited tumor cell growth. Treatment of FaDu tumor with a therapeutic dose of irinotecan resulted in depression of xCT protein levels, leading to tumor growth retardation and downregulation of GSH with increased reactive oxygen species (ROS). The accumulation of ROS correlated with increased DNA damage as evidenced by increased H2AX. Conclusion: Depression of xCT protein by irinotecan resulted in downregulation of GSH and increase in ROS, which could be the other possible mechanisms of DNA damage by irinotecan.",
keywords = "Glutathione, Irinotecan, P-H2AX, SN-38, XCT",
author = "Sreenivasulu Chintala and K{\'a}roly T{\'o}th and Yin, {Ming Biao} and Arup Bhattacharya and Smith, {Sylvia B} and Ola, {M. Shamsul} and Shousong Cao and Durrani, {Farukh A.} and Zinia, {Tanjima R.} and Rebecca Dean and Slocum, {Harry K.} and Rustum, {Youcef M.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1159/000316334",
language = "English (US)",
volume = "56",
pages = "223--233",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Downregulation of cystine transporter xc- by irinotecan in human head and neck cancer FaDu xenografts

AU - Chintala, Sreenivasulu

AU - Tóth, Károly

AU - Yin, Ming Biao

AU - Bhattacharya, Arup

AU - Smith, Sylvia B

AU - Ola, M. Shamsul

AU - Cao, Shousong

AU - Durrani, Farukh A.

AU - Zinia, Tanjima R.

AU - Dean, Rebecca

AU - Slocum, Harry K.

AU - Rustum, Youcef M.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Background: The purpose of this study was: (1) to document the critical requirement of cystine for growth of human tumor cells in vitro, and (2) to determine the effect of the anticancer agent irinotecan on the cystine transporter xc- in head and neck FaDu xenografts. Methods: Cell growth was measured by sulforhodamine B assay. xCT protein, glutathione (GSH) and DNA damage were determined using Western blot, spectrophotometry, and immunohistochemistry, respectively. Results: Depletion of cystine from the medium inhibited tumor cell growth. Treatment of FaDu tumor with a therapeutic dose of irinotecan resulted in depression of xCT protein levels, leading to tumor growth retardation and downregulation of GSH with increased reactive oxygen species (ROS). The accumulation of ROS correlated with increased DNA damage as evidenced by increased H2AX. Conclusion: Depression of xCT protein by irinotecan resulted in downregulation of GSH and increase in ROS, which could be the other possible mechanisms of DNA damage by irinotecan.

AB - Background: The purpose of this study was: (1) to document the critical requirement of cystine for growth of human tumor cells in vitro, and (2) to determine the effect of the anticancer agent irinotecan on the cystine transporter xc- in head and neck FaDu xenografts. Methods: Cell growth was measured by sulforhodamine B assay. xCT protein, glutathione (GSH) and DNA damage were determined using Western blot, spectrophotometry, and immunohistochemistry, respectively. Results: Depletion of cystine from the medium inhibited tumor cell growth. Treatment of FaDu tumor with a therapeutic dose of irinotecan resulted in depression of xCT protein levels, leading to tumor growth retardation and downregulation of GSH with increased reactive oxygen species (ROS). The accumulation of ROS correlated with increased DNA damage as evidenced by increased H2AX. Conclusion: Depression of xCT protein by irinotecan resulted in downregulation of GSH and increase in ROS, which could be the other possible mechanisms of DNA damage by irinotecan.

KW - Glutathione

KW - Irinotecan

KW - P-H2AX

KW - SN-38

KW - XCT

UR - http://www.scopus.com/inward/record.url?scp=77953334224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953334224&partnerID=8YFLogxK

U2 - 10.1159/000316334

DO - 10.1159/000316334

M3 - Article

VL - 56

SP - 223

EP - 233

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 3

ER -